
Naveen L Pereira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9006679/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Updated Expert Consensus Statement on Platelet Function and Genetic Testing forÂGuiding P2Y12 Receptor Inhibitor Treatment in Percutaneous CoronaryÂIntervention. JACC: Cardiovascular Interventions, 2019, 12, 1521-1537.	2.9	366
2	Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2020, 324, 761.	7.4	257
3	Clopidogrel Pharmacogenetics. Circulation: Cardiovascular Interventions, 2019, 12, e007811.	3.9	139
4	Genetics of dilated cardiomyopathy: practical implications for heart failure management. Nature Reviews Cardiology, 2020, 17, 286-297.	13.7	133
5	Spectrum of Restrictive and InfiltrativeÂCardiomyopathies. Journal of the American College of Cardiology, 2018, 71, 1130-1148.	2.8	91
6	Effect of CYP2C19 Genotype on IschemicÂOutcomes During OralÂP2Y12ÂInhibitor Therapy. JACC: Cardiovascular Interventions, 2021, 14, 739-750.	2.9	90
7	Long-Term Sirolimus for PrimaryÂlmmunosuppression in HeartÂTransplantÂRecipients. Journal of the American College of Cardiology, 2018, 71, 636-650.	2.8	81
8	Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. European Heart Journal, 2022, 43, 959-967.	2.2	79
9	Donor-Specific Antibodies to Class II Antigens Are Associated With Accelerated Cardiac Allograft Vasculopathy. Transplantation, 2013, 95, 389-396.	1.0	65
10	Changes in Cardiopulmonary Exercise Testing Parameters Following Continuous Flow Left Ventricular Assist Device Implantation and Heart Transplantation. Journal of Cardiac Failure, 2014, 20, 548-554.	1.7	65
11	Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine. Journal of Personalized Medicine, 2018, 8, 8.	2.5	65
12	Developing EHR-driven heart failure risk prediction models using CPXR(Log) with the probabilistic loss function. Journal of Biomedical Informatics, 2016, 60, 260-269.	4.3	64
13	COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine. Mayo Clinic Proceedings, 2021, 96, 446-463.	3.0	62
14	Cardiovascular pharmacogenomics and individualized drug therapy. Nature Reviews Cardiology, 2009, 6, 632-638.	13.7	61
15	Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovascular Pathology, 2013, 22, 189-194.	1.6	52
16	Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devicesa~†. Interactive Cardiovascular and Thoracic Surgery, 2010, 11, 503-505.	1.1	48
17	Spectrum of Restrictive and InfiltrativeÂCardiomyopathies. Journal of the American College of Cardiology, 2018, 71, 1149-1166.	2.8	48
18	Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association. Circulation Genomic and Precision Medicine, 2019, 12, 458-485.	3.6	39

#	Article	IF	CITATIONS
19	Incidence of Malignancies in Patients Treated With Sirolimus Following HeartÂTransplantation. Journal of the American College of Cardiology, 2019, 73, 2676-2688.	2.8	38
20	Genotype-based clinical trials in cardiovascular disease. Nature Reviews Cardiology, 2015, 12, 475-487.	13.7	37
21	Preoperative Determinants of Quality of Life and Functional Capacity Response to Left Ventricular Assist Device Therapy. Journal of Cardiac Failure, 2016, 22, 797-805.	1.7	33
22	The Role of Medical Management for Acute Intravascular Hemolysis in Patients Supported on Axial Flow LVAD. ASAIO Journal, 2014, 60, 9-14.	1.6	32
23	Advanced Cardiac Amyloidosis Associated withÂNormal Interventricular Septal Thickness: AnÂUncommon Presentation of Infiltrative Cardiomyopathy. Journal of the American Society of Echocardiography, 2014, 27, 440-447.	2.8	30
24	Implementation of preemptive DNA sequence–based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. Genetics in Medicine, 2022, 24, 1062-1072.	2.4	28
25	Proximal thoracic aorta dimensions after continuous-flow left ventricular assist device implantation: Longitudinal changes and relation to aortic valve insufficiency. Journal of Heart and Lung Transplantation, 2016, 35, 423-432.	0.6	27
26	Natriuretic peptide pharmacogenetics: Membrane metallo-endopeptidase (MME): Common gene sequence variation, functional characterization and degradation. Journal of Molecular and Cellular Cardiology, 2010, 49, 864-874.	1.9	24
27	Contemporary Strategies in the Diagnosis and Management of Heart Failure. Mayo Clinic Proceedings, 2014, 89, 662-676.	3.0	24
28	Circulating Galectin-3 Levels AreÂPersistently Elevated After HeartÂTransplantation and Are AssociatedÂWithÂRenal Dysfunction. JACC: Heart Failure, 2016, 4, 847-856.	4.1	23
29	Kidney transplantation as a therapeutic option for end-stage renal disease developing after heart transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 297-304.	0.6	23
30	ABCDâ€GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILORâ€PCI Trial. Journal of the American Heart Association, 2022, 11, e024156.	3.7	22
31	Circulating Neprilysin in Patients WithÂHeartÂFailure and Preserved EjectionÂFraction. JACC: Heart Failure, 2020, 8, 70-80.	4.1	21
32	Sex Related Differences in the Risk of Antibody-Mediated Rejection and Subsequent Allograft Vasculopathy Post-Heart Transplantation: A Single-Center Experience. Transplantation Direct, 2016, 2, e106.	1.6	19
33	Sirolimus Therapy Is Associated with Elevation in Circulating PCSK9 Levels in Cardiac Transplant Patients. Journal of Cardiovascular Translational Research, 2017, 10, 9-15.	2.4	18
34	Heart-After-Liver Transplantation Attenuates Rejection of Cardiac Allografts in Sensitized Patients. Journal of the American College of Cardiology, 2021, 77, 1331-1340.	2.8	18
35	TPMT genetic variants are associated with increased rejection with azathioprine use in heart transplantation. Pharmacogenetics and Genomics, 2013, 23, 658-665.	1.5	17
36	Circulating Atrial Natriuretic Peptide Genetic Association Study Identifies a Novel Gene Cluster Associated With Stroke in Whites. Circulation: Cardiovascular Genetics, 2015, 8, 141-149.	5.1	17

#	Article	IF	CITATIONS
37	Pharmacogenetics of Clopidogrel. Circulation: Cardiovascular Genetics, 2016, 9, 185-188.	5.1	15
38	Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease. Journal of the American Heart Association, 2019, 8, e012943.	3.7	15
39	Rapid Exclusion of COVID Infection With the Artificial Intelligence Electrocardiogram. Mayo Clinic Proceedings, 2021, 96, 2081-2094.	3.0	15
40	Artificial Intelligence-Enabled Electrocardiography to Screen Patients with Dilated Cardiomyopathy. American Journal of Cardiology, 2021, 155, 121-127.	1.6	15
41	Predictors and Outcomes of Renal Replacement Therapy After Left Ventricular Assist Device Implantation. Mayo Clinic Proceedings, 2019, 94, 1003-1014.	3.0	13
42	International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing. Pharmacogenetics and Genomics, 2019, 29, 76-83.	1.5	13
43	Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure. Korean Circulation Journal, 2021, 51, 797.	1.9	13
44	Cardiac allograft hypertrophy is associated with impaired exercise tolerance after heart transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 1153-1160.	0.6	12
45	Natriuretic Peptide Receptor-3 Gene (NPR3). Circulation: Cardiovascular Genetics, 2013, 6, 201-210.	5.1	12
46	The Role of Donor-Specific Antibodies in Acute Cardiac Allograft Dysfunction in the Absence of Cellular Rejection. Transplantation, 2014, 98, 229-238.	1.0	12
47	Importance of Routine Antihuman/Leukocyte Antibody Monitoring. Circulation, 2017, 136, 1350-1352.	1.6	12
48	Elevated <scp>ST</scp> 2 levels are associated with antibodyâ€mediated rejection in heart transplant recipients. Clinical Transplantation, 2018, 32, e13349.	1.6	12
49	Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients. Journal of Heart and Lung Transplantation, 2018, 37, 1372-1380.	0.6	11
50	Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry. American Heart Journal, 2021, 232, 84-93.	2.7	10
51	Clinical Impact of Secondary Risk Factors in <i>TTN</i> -Mediated Dilated Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003240.	3.6	10
52	A Functional Genetic Variant (N521D) in Natriuretic Peptide Receptor 3 Is Associated with Diastolic Dysfunction: The Prevalence of Asymptomatic Ventricular Dysfunction Study. PLoS ONE, 2014, 9, e85708.	2.5	9
53	Clinical Implementation of Cardiovascular Pharmacogenomics. Mayo Clinic Proceedings, 2015, 90, 701-704.	3.0	8
54	Time to achieving therapeutic international normalized ratio increases hospital length of stay after heart valve replacement surgery. American Heart Journal, 2017, 187, 70-77.	2.7	8

#	Article	IF	CITATIONS
55	Genomewide association study reveals novel genetic loci associated with change in renal function in heart transplant recipients. Clinical Transplantation, 2018, 32, e13395.	1.6	8
56	International Analysis of LVAD Point-of-Care Versus Plasma INR: A Multicenter Study. ASAIO Journal, 2018, 64, e161-e165.	1.6	7
57	Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. Cardiovascular Drugs and Therapy, 2021, 35, 549-559.	2.6	6
58	Genotype-Guided P2Y ₁₂ Inhibitor Therapy After Percutaneous Coronary Intervention: A Bayesian Analysis. Circulation Genomic and Precision Medicine, 2021, 14, CIRCGEN121003353.	3.6	6
59	Rare Genetic Variants Associated With Myocardial Fibrosis: Multi-Ethnic Study of Atherosclerosis. Frontiers in Cardiovascular Medicine, 2022, 9, 804788.	2.4	6
60	De Novo Development of Eosinophilic Myocarditis With Left Ventricular Assist Device Support as Bridge to Transplant. Annals of Thoracic Surgery, 2010, 90, 1345-1347.	1.3	5
61	Nonhuman leukocyte antigen antibodies that have impact in the heart transplant patient. Current Opinion in Organ Transplantation, 2019, 24, 279-285.	1.6	5
62	Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Study. Journal of Clinical Medicine, 2022, 11, 322.	2.4	5
63	Previously Unreported in Women <i>Galactosidase Alpha</i> Pro409Ser Variant Is Associated With Fabry Disease. Circulation: Cardiovascular Genetics, 2017, 10, e001661.	5.1	4
64	Expanding Spectrum of Desmin-Related Myopathy, Long-term Follow-up, and Cardiac Transplantation. Neurology, 2021, 97, e1150-e1158.	1.1	4
65	Shotgun Immunoproteomics for Identification of Nonhuman Leukocyte Antigens Associated With Cellular Dysfunction in Heart Transplant Rejection. Transplantation, 2022, 106, 1376-1389.	1.0	4
66	Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas à cause du BNP?. European Journal of Heart Failure, 2019, 21, 609-612.	7.1	3
67	Rare TBX4 Variant Causing Pulmonary Arterial Hypertension With Small Patella Syndrome in an Adult Man. JACC: Case Reports, 2021, 3, 1447-1452.	0.6	3
68	Small bowel bleeding in patients with left ventricular assist device: outcomes of conservative therapy versus balloonâ€'assisted enteroscopy. Annals of Gastroenterology, 2018, 31, 692-697.	0.6	2
69	Patient Onboarding and Engagement to Build a Digital Study After Enrollment in a Clinical Trial (TAILOR-PCI Digital Study): Intervention Study. JMIR Formative Research, 2022, 6, e34080.	1.4	2
70	Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devices: a time for reappraisal. Interactive Cardiovascular and Thoracic Surgery, 2010, 11, 505-506.	1.1	1
71	Updates on the Genetic Paradigm in Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 37.	0.9	1
72	Galectina-3 como biomarcador en el trasplante cardiaco: ¿hacia la medicina de precisión?. Revista Espanola De Cardiologia, 2019, 72, 889-891.	1.2	1

#	Article	IF	CITATIONS
73	Sex‧pecific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILORâ€PCI Trial. Journal of the American Heart Association, 2022, 11, .	3.7	1
74	Genetic Risk and Altering Lipids With Lifestyle Changes and Metformin. Circulation: Cardiovascular Genetics, 2016, 9, 469-471.	5.1	0
75	Personalizing Antiplatelet Therapies for Acute Coronary Syndrome (ACS) in Patients Undergoing Percutaneous Coronary Intervention (PCI): Are They Cost-effective?. Cardiovascular Drugs and Therapy, 2017, 31, 1-3.	2.6	0
76	Response by Wong et al to Letter Regarding Article, "Importance of Routine Antihuman/Leukocyte Antibody Monitoring: De Novo Donor Specific Antibodies Are Associated With Rejection and Allograft Vasculopathy After Heart Transplantation― Circulation, 2018, 137, 1872-1873.	1.6	0
77	Unraveling the Puzzle of the Role of Heritability in the Variability of the QT Interval Using Exome Array Analysis. Circulation Genomic and Precision Medicine, 2018, 11, e002007.	3.6	0
78	Prognostic Biomarkers for Precision Medicine in Heart Transplant: Is Galectin-3 the One?. Revista Espanola De Cardiologia (English Ed), 2019, 72, 889-891.	0.6	0
79	The Role of Genetic Testing in the Evaluation of Dilated Cardiomyopathies. Case Reports in Cardiology, 2021, 2021, 1-4.	0.2	0
80	In reply—COVID-19: Precision Medicine and Vascular Endothelium. Mayo Clinic Proceedings, 2021, 96, 1672.	3.0	0
81	Reply. JACC: Cardiovascular Interventions, 2021, 14, 1501.	2.9	0
82	Point of care CYP2C19 genotyping after percutaneous coronary intervention. Pharmacogenomics Journal, 2022, , .	2.0	0